戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 omyopathy (some of which display endocardial fibroelastosis).
2 dilated cardiomyopathy (DCM) and endocardial fibroelastosis.
3 ulmonary hypertension, valvular disease, and fibroelastosis.
4 valuation and diagnosis of pleuroparenchymal fibroelastosis.
5  by visceral pleural fibrosis and subpleural fibroelastosis.
6 f all cases included hydrops and endocardial fibroelastosis.
7 e at a lower risk of hydrops and endocardial fibroelastosis.
8 ndary outcomes included isolated endocardial fibroelastosis, 1 degrees CHB at birth and skin rash.
9 axis ratio) - 0.79 (grade 2 or 3 endocardial fibroelastosis) - 6.78.
10  bronchiolitis (OB) and restrictive alveolar fibroelastosis (AFE), which have distinct clinical prese
11  pathological cascade leading to endocardial fibroelastosis and DCM.
12 is a new susceptibility gene for endocardial fibroelastosis and DCM.
13 f rare entities, including pleuroparenchymal fibroelastosis and rare histologic patterns, is introduc
14 of postnatal death were hydrops, endocardial fibroelastosis, and lower ventricular rate.
15 tract obstructions, resection of endocardial fibroelastosis, and promotion of flow through the LV.
16 tly, two distinct types of pleuroparenchymal fibroelastosis are recognized: the idiopathic type for c
17 Finally, the near-eradication of endocardial fibroelastosis associated with persistent mumps virus in
18 logical characteristics of pleuroparenchymal fibroelastosis, discussing the different associations wi
19                                  Endocardial fibroelastosis (EFE) is a unique form of fibrosis, which
20 dy-mediated fetal cardiomyopathy/endocardial fibroelastosis following intravenous gamma globulin (IVI
21 cardial samples of patients with endocardial fibroelastosis for the viral genome.
22 0.75]; P=0.001), the presence of endocardial fibroelastosis (HR, 2.61 [95% CI, 1.48-4.51]; P=0.001),
23 , supporting the hypothesis that endocardial fibroelastosis is a sequela of a viral myocarditis, in p
24           The diagnosis of pleuroparenchymal fibroelastosis must be managed from a combined clinical
25 Secondary outcomes included mild endocardial fibroelastosis (n = 1) and cutaneous neonatal lupus (n =
26 cant decline in the incidence of endocardial fibroelastosis occurred.
27                            Pleuroparenchymal fibroelastosis (PPFE) is an interstitial lung disease (I
28                                  Endocardial fibroelastosis, previously a common disease of children,
29 nce of dilated cardiomyopathy or endocardial fibroelastosis quadrupled the case fatality rate.
30        The term idiopathic pleuroparenchymal fibroelastosis refers to a rare interstitial lung diseas
31 r AoV surgery, while concomitant endocardial fibroelastosis resection at AoV surgery had a protective
32                      Concomitant endocardial fibroelastosis resection is recommended at AoV surgery f
33 dy-mediated fetal cardiomyopathy/endocardial fibroelastosis suffer demise or need for transplant.
34 ogic role for viral infection in endocardial fibroelastosis, supporting the hypothesis that endocardi
35                                  Endocardial fibroelastosis was seen in 16 and was not obvious in 4 o
36  29 patients with autopsy-proven endocardial fibroelastosis were analyzed for viral genome (enterovir
37 dy-mediated fetal cardiomyopathy/endocardial fibroelastosis with IVIG and corticosteroids potentially